Funding sources: This work was supported by Novartis, East Hanover, NJ, U.S.A.
The effect of pimecrolimus on innate immunity in subjects with atopic dermatitis: a double-blind, randomized, vehicle-controlled study
Version of Record online: 5 SEP 2012
© 2012 The Authors. BJD © 2012 British Association of Dermatologists
British Journal of Dermatology
Volume 168, Issue 2, pages 426–428, February 2013
How to Cite
Afshar, M., Kotol, P., Miller, J., Gallo, R. and Hata, T. (2013), The effect of pimecrolimus on innate immunity in subjects with atopic dermatitis: a double-blind, randomized, vehicle-controlled study. British Journal of Dermatology, 168: 426–428. doi: 10.1111/j.1365-2133.2012.11052.x
Conflicts of interest: This work was supported by Novartis, East Hanover, NJ, USA.
- Issue online: 30 JAN 2013
- Version of Record online: 5 SEP 2012
- Accepted manuscript online: 12 MAY 2012 09:50AM EST
Table S1. Descriptive summary of subject characteristics by diagnostic group.
Data S1. Reverse transcriptase–polymerasechain reaction methods supplement.
Data S2. Statistical supplement.
|bjd11052_sm_Pimecrolimus-Supporting-Information.doc||39K||Supporting info item|
|bjd11052_sm_TableS1-DataS1-S2.doc||39K||Supporting info item|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.